Antonetti Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Antonetti Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$8.85K	Hold	100	–	–	0.01%	213
2023 Q2	$8.67K	Hold	100	–	–	0.01%	230
2023 Q1	$9.72K	Hold	100	–	–	0.01%	221
2022 Q4	$10.3K	Hold	100	–	–	0.01%	218
2022 Q3	$8K	Hold	100	–	–	0.01%	230
2022 Q2	$8K	Hold	100	–	–	0.01%	233
2022 Q1	$8K	Hold	100	–	–	0.01%	267
2021 Q4	$9K	Hold	100	–	–	0.01%	310
2021 Q3	$8K	Buy	+100	New	+$7.89K	0.01%	330

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Antonetti Capital Management's BMRN Position: Q3 2023 in Review

Antonetti Capital Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2023 at 100 shares worth $8.85K. The position accounts for 0.01% of the portfolio, ranked #213.

Antonetti Capital Management first reported a position in BMRN in Q3 2021 and has held it in 9 quarters since. The position peaked at $10.3K in Q4 2022. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Antonetti Capital Management held 100 shares of BioMarin Pharmaceuticals worth $8.85K as of Q3 2023.
Antonetti Capital Management left its BioMarin Pharmaceuticals share count unchanged in Q3 2023.
BioMarin Pharmaceuticals made up 0.01% of Antonetti Capital Management's portfolio in Q3 2023, its #213 holding.
Antonetti Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2021 and has held it in 9 quarters since.
Antonetti Capital Management's BioMarin Pharmaceuticals position peaked at $10.3K in Q4 2022.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Antonetti Capital Management's 13F filing for Q3 2023, filed 9 Nov 2023.